Drug
Plozalizumab clinical trials
Also written MLN1202.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Name
Studies by the year they started
7 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2010 | 1 |
| 2015 | 2 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 1
Millennium Pharmaceuticals, Inc. (3) · Takeda (3) · SWOG Cancer Research Network (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses plozalizumab is read from its arms, and is right about nine times in ten.
Testing it · 7
- Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02723006Written as TAK-202
- S0916, MLN1202 in Treating Patients With Bone MetastasesCompletedPhase 2SWOG Cancer Research NetworkNCT01015560Written as anti-CCR2 monoclonal antibody MLN1202
- Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With MacroalbuminuriaWithdrawnPhase 2TakedaNCT02410499Written as MLN1202
- Phase 1 Single Subcutaneous Dose Study of MLN1202WithdrawnPhase 1TakedaNCT02426021Written as MLN1202
- Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular DiseaseWithdrawnPhase 2TakedaNCT02388971Written as MLN1202
- Study of the Safety and Efficacy of MLN1202 in Patients in Multiple SclerosisCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT01199640Written as MLN1202
- Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular DiseaseCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT00715169Written as MLN1202
Codes
What other systems call plozalizumab · ClinicalTrials.gg INT005835
- MeSH (NLM) C558499plozalizumabOne source NLM
- UNII (FDA) 4XG66BMN0DPLOZALIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q25326699PlozalizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88308PlozalizumabOne source FDA
- DrugBank DB12520One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C558499 | plozalizumab | One source NLM |
| UNII (FDA) | 4XG66BMN0D | PLOZALIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q25326699 | Plozalizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88308 | Plozalizumab | One source FDA |
| DrugBank | DB12520 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.